Investing Profile

Dan Becker

InvestorVC
Managing Director at Access Biotechnology
accessbio-tech.comNew York, New York
Photo of Dan Becker, Managing Director at Access Biotechnology

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
Access Biotechnology Managing Director
$100K - $5.0M
$1.5M
13
CompanyStageDateRound SizeTotal Raised
Day One Biopharmaceuticals
Post Ipo EquityJul 2024$180M
Series BFeb 2021$130M
Series AMay 2020$60M
$370M
Co-investors: Julie Grant (Canaan Partners), Derek DiRocco (RA Capital), Michael Gladstone (Atlas Venture)
GRO Biosciences
Series BJul 2024$60M
$91M
Co-investors: Geoffrey Smith (Digitalis Ventures), Dror Berman (Innovation Endeavors), Ameena El-Bibany (Artis Ventures (AV)), Russ Wilcox (Pillar VC), Kevin Bitterman (Atlas Venture)
Mariana Oncology
Series BSep 2023$180M
Series ADec 2021$75M
$250M
Co-investors: Geert-Jan Mulder (Forbion), Kevin Bitterman (Atlas Venture), Josh Resnick
Hemab
Series BFeb 2023$140M
$140M
Co-investors: Uya Chuluunbaatar (Amzak Health Investors), Christine Borowski (Access Biotechnology)
Zurp
Pre SeedJan 2023$5M
$5M
Co-investors: Amy Wu (Menlo Ventures), Lenny Rachitsky (AirAngels), David Weisburd (10X Capital), Julia Lipton (Awesome People Ventures), Pascal Unger (Darling Ventures), Dhani Jones (QEY Capital), Daniel Darling (Darling Ventures), Scott Belsky, Siqi Chen, Shane Neman, Niklas Jansen, Baron Davis, Bobby Goodlatte, Nik Sharma
ACELYRIN
Series CSep 2022$300M
$560M
Co-investors: Beth Seidenberg (Westlake Village BioPartners), Richard Gaster (venBio), Sean Harper
Curie Therapeutics
Series ADec 2021$75M
$75M
Co-investors: Kevin Bitterman (Atlas Venture)
DTx Pharma
Series BMar 2021$100M
$140M
Co-investors: Andrew Adams (Oak HC/FT), Martin Alexander Gershon (Endeavor Venture Funds), Cristina Escoda (Tachyon Ventures)